Alize Pharma closes Euro 3m financing round
Alize Pharma, a French-based group of biopharmaceutical companies developing innovative therapeutics for metabolic diseases and cancer, has raised Euro 3m of funding.
Alize Pharma, a French-based group of biopharmaceutical companies developing innovative therapeutics for metabolic diseases and cancer, has raised Euro 3m of funding.
The funding will allow Alize Pharma to strengthen its drug development team and pursue its development programmes. It will also facilitate partnership discussions. Currently, the group has two programmes at the preclinical stage; these are being handled by two distinct entities - Alize Pharma and Alize Pharma II.
The first programme, AZP-01, aims at developing the first product of a new therapeutic class, unacylated ghrelin agonists, for the treatment of Type II diabetes. The second, Asparec (AZP-02), is a new recombinant long-acting L-asparaginase product with reduced immunogenicity. It has been developed in the treatment of acute lymphoblastic leukemia.
The funds raised will allow Alize Pharma to finalise the optimisation and formulation of a first drug candidate for AZP-01 and to file a clinical trial application to undertake the clinical development of the Asparec product.